Driven by Our Promise
It began with a promise. CSL Behring's parent company, CSL, was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We are CSL Behring and we are driven by our promise.
For further information on our parent company and investing with us, visit CSL.com.
Focus on Serious & Rare Diseases
CSL Behring's portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency.See How We're Leading the Way
Our Company Structure
Global biotechnology leader CSL Behring, the world's largest collector of human plasma CSL Plasma, and a world leader in influenza vaccines Seqirus, all fall under our parent company, CSL Limited. CSL Limited is based in Melbourne, Victoria, Australia, and is traded on the Australian Securities Exchange (ASX) under the symbol CSL.
CSL Behring’s strong commitment to living our Values has guided us for many decades. Our Values have been fundamental to our success -- helping us to save lives, protect the health of people, and earn our reputation as a trusted and reliable global biotechnology leader. They’re at the core of how our employees interact with each other, make decisions and solve problems. They are:
We deliver on our promise to patients.
We turn innovative thinking into solutions.
We walk the talk.
We are stronger together.
We take pride in our results.